Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 ± empagliflozin in compensated cirrhosis with clinically significant portal hypertension
2023-504257-12-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial in Portal Hypertension (PH) and Cirrhosis comparing BI 685509 monotherapy with BI 685509 + empagliflozin (2 arms). Primary endpoint: Percentage change in hepatic venous pressure gradient (HVPG) from baseline after 8 weeks of treatment. Started May 2023; status: completed.
02
Drugs
avenciguatempagliflozin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2023-504257-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504257-12-00.